Cardinal Health raises FY25 EPS guidance to $7.85-$8 amid specialty growth and acquisitions
Q2 2025 Management View CEO Jason Hollar emphasized strong Q2 performance driven by robust demand in Pharmaceutical and ...
Cardinal Health’s Strong Performance and Strategic Acquisitions Justify Buy Rating
Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...
Modern Healthcare16h
Cardinal Health CEO Jason Hollar issues warning on tariffs
Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...
Cardinal Health (NYSE:CAH) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
Cardinal Health (NYSE:CAH – Get Free Report) had its target price hoisted by equities researchers at Wells Fargo & Company from $127.00 to $135.00 in a research note issued on Wednesday,Benzinga ...
Cardinal Health lifts 2025 profit forecast on specialty drugs demand
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
Hoodline16h
Dublin City Schools Abandons Cardinal Health Building Purchase, Opts for Scioto High School Expansion
Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...
Positive Financial Prospects Drive Buy Rating for Cardinal Health Amid Raised Guidance and Strong Segment Performance
Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Cardinal Health (CAH – Research Report). The associated price target was ...
Cardinal Health may raise prices to offset potential tariffs
By Christy Santhosh and Kamal Choudhury (Reuters) -Drug distributor Cardinal Health said on Thursday it may need to increase prices of some of its products if the proposed tariffs on Mexico go into ...
Drug Store News19h
Cardinal Health reports Q2 results, raises fiscal year 2025 outlook
Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.
MDM16h
Cardinal Health 2Q Sales Rise 16% Outside of Optimum Impact
Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.
Citi raises Cardinal Health stock target to $130 on Pharma strength
Citi analyst Daniel Grosslight increased the price target for Cardinal Health (NYSE:CAH) shares to $130 from the previous $129, while keeping a Neutral rating on the stock. The adjustment follows ...